- Report
- March 2024
- 193 Pages
Global
From €3277EUR$3,374USD£2,827GBP
€3641EUR$3,749USD£3,141GBP
- Report
- February 2024
- 175 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Drug Pipelines
- January 2024
- 60 Pages
Global
From €1457EUR$1,500USD£1,257GBP
- Report
- November 2023
- 293 Pages
Global
€4851EUR$4,995USD£4,185GBP
- Report
- November 2020
- 450 Pages
Global
From €4759EUR$4,900USD£4,106GBP
- Report
- July 2022
- 2190 Pages
Global
From €3497EUR$3,600USD£3,016GBP
- Report
- January 2020
- 300 Pages
Global
From €3205EUR$3,300USD£2,765GBP
- Report
- July 2022
- 200 Pages
Global
From €4055EUR$4,175USD£3,498GBP
- Report
- June 2022
- 111 Pages
Global
From €4614EUR$4,750USD£3,980GBP
- Report
- February 2023
- 100 Pages
Global
From €2671EUR$2,750USD£2,304GBP
- Report
- July 2022
- 100 Pages
Global
From €2671EUR$2,750USD£2,304GBP
- Report
- March 2022
- 120 Pages
Global
From €2428EUR$2,500USD£2,095GBP
From €116EUR$119USD£100GBP
- Book
- September 2009
- 400 Pages
- Book
- November 2016
- 330 Pages
The Cancer Drug Development market is a subset of the larger Drug Discovery industry. It focuses on the development of drugs to treat cancer, a disease that affects millions of people worldwide. This market includes the research and development of new drugs, as well as the testing and approval of existing drugs for use in cancer treatment. Companies in this market must adhere to strict regulations and guidelines set by regulatory bodies such as the US Food and Drug Administration (FDA).
The Cancer Drug Development market is highly competitive, with many companies vying for a share of the market. Companies in this market include large pharmaceutical companies, biotechnology companies, and smaller start-ups. Examples of companies in this market include AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more
